- Home
- CTSO vs SER Comparison
CTSO vs SER Comparison
Compare CTSO & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- SER
- Stock Information
- Founded
- CTSO 1997
- SER 2017
- Country
- CTSO United States
- SER United States
- Employees
- CTSO N/A
- SER N/A
- Industry
- CTSO Medical/Dental Instruments
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- SER Health Care
- Exchange
- CTSO Nasdaq
- SER Nasdaq
- Market Cap
- CTSO 61.7M
- SER 53.1M
- IPO Year
- CTSO N/A
- SER 2018
- Fundamental
- Price
- CTSO $0.90
- SER $4.72
- Analyst Decision
- CTSO Buy
- SER Strong Buy
- Analyst Count
- CTSO 2
- SER 2
- Target Price
- CTSO $5.50
- SER $13.00
- AVG Volume (30 Days)
- CTSO 130.7K
- SER 339.1K
- Earning Date
- CTSO 11-06-2025
- SER 11-11-2025
- Dividend Yield
- CTSO N/A
- SER N/A
- EPS Growth
- CTSO N/A
- SER N/A
- EPS
- CTSO N/A
- SER N/A
- Revenue
- CTSO $36,107,520.00
- SER $130,000.00
- Revenue This Year
- CTSO $11.93
- SER $17.23
- Revenue Next Year
- CTSO $21.22
- SER N/A
- P/E Ratio
- CTSO N/A
- SER N/A
- Revenue Growth
- CTSO 20.18
- SER N/A
- 52 Week Low
- CTSO $0.71
- SER $3.81
- 52 Week High
- CTSO $1.61
- SER $10.28
- Technical
- Relative Strength Index (RSI)
- CTSO 42.05
- SER 37.89
- Support Level
- CTSO $0.87
- SER $4.90
- Resistance Level
- CTSO $1.04
- SER $5.25
- Average True Range (ATR)
- CTSO 0.05
- SER 0.28
- MACD
- CTSO -0.00
- SER -0.04
- Stochastic Oscillator
- CTSO 21.95
- SER 0.00
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.